Valuation: ABVC BioPharma, Inc.

Market Cap 23.07M 19.75M 18.43M 16.91M 31.78M 2.21B 32.4M 219M 85.23M 1.11B 86.62M 84.74M 3.66B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 25.8M 22.09M 20.61M 18.91M 35.53M 2.47B 36.23M 244M 95.3M 1.24B 96.86M 94.75M 4.1B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.7%
Yield 2024 *
-
Yield 2025 -
1 day-4.97%
1 week-7.24%
Current month-11.89%
1 month-25.84%
3 months-19.10%
6 months-41.07%
Current year-58.22%
1 week 0.82
Extreme 0.8208
0.96
1 month 0.82
Extreme 0.8208
1.26
Current year 0.82
Extreme 0.8208
2.43
1 year 0.82
Extreme 0.8208
3.4
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 23/06/2023
Chief Executive Officer 39 01/07/2015
Chief Tech/Sci/R&D Officer 72 13/06/2023
Director TitleAgeSince
Chairman 39 01/07/2015
Director/Board Member 65 23/11/2017
Director/Board Member 55 23/11/2017
Date Insider Type Main position Quantity % Market Cap.
5/20/22 A Other

Chairman

7,908,805 26.0954%
8/2/21 A Other

Director

5,949 0.0243%
8/2/21 A Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
-4.97%-7.24%-71.20%-52.41% 23.07M
+2.38%+3.43%+82.88%+115.89% 73.96B
-0.36%+20.79%+53.12%+93.38% 64.66B
-4.27%-0.99%-3.38%+475.61% 27.32B
-1.97%+20.38%-0.37%+0.48% 27.86B
+2.74%+12.98%+62.84%+28.14% 25.97B
-0.37%+5.23%+35.51%-14.51% 19.98B
-1.79%-4.84%+239.54%+414.48% 17.84B
+0.94%+3.36%+18.55%+532.94% 16.24B
-1.29%+6.09%+41.81%+154.45% 13.3B
Average -0.90%+4.84%+45.93%+174.85% 28.72B
Weighted average by Cap. +0.04%+8.21%+58.97%+160.75%

Financials

2024 2025
Net sales 510K 436K 407K 374K 702K 48.76M 716K 4.83M 1.88M 24.44M 1.91M 1.87M 80.9M -
Net income -4.9M -4.2M -3.92M -3.59M -6.75M -469M -6.89M -46.46M -18.11M -235M -18.41M -18.01M -778M -7.91M -6.77M -6.32M -5.8M -10.89M -757M -11.11M -74.95M -29.22M -379M -29.7M -29.05M -1.26B
Net Debt 2.88M 2.47M 2.3M 2.11M 3.97M 276M 4.05M 27.31M 10.65M 138M 10.82M 10.59M 458M 2.73M 2.34M 2.18M 2M 3.76M 261M 3.83M 25.85M 10.08M 131M 10.24M 10.02M 433M
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
-
Date Price Change Volume
20/08/26 $0.8899 -4.97% 97,769
19/08/26 $0.9364 +8.12% 117,019
18/08/26 $0.8661 +1.91% 88,168
17/08/26 $0.8499 -5.56% 127,032
14/08/26 $0.8999 -6.20% 116,869
  1. Stock Market
  2. Stocks
  3. ABVC Stock